Country/Region

September 15, 2014

 

On September 15, Gilead Sciences is expected to announce agreements with a handful of Indian pharmaceutical manufacturers to produce and sell generic versions of two new Hepatitis C drugs—sofosbuvir and ledipasvir. Approximately 180 million people live with Hepatitis C today, with 350,000 people dying annually of the disease.

June 26, 2013

MSF testifies in Congress on India's right to keep lifesaving medicines affordable.

September 27, 2012

In this blog post from BMJ Group Blogs, lawyer and India manager of MSF's Access Campaign Leena Menghaney discusses the two legal battles that are taking center stage in the struggle over India's medicines patent law.

March 02, 2012

MSF's appeal to Novartis to drop its case against India continues as the pharmaceutical company's day in court draws near.

November 09, 2011

Kala azar, a disease transmitted by certain types of sand flies, is endemic in much of Bihar. It causes enlargement of the spleen and, if left untreated, is fatal for virtually all patients.

November 04, 2010

In 2005, India put in place a patent law—fortunately it’s a law that supports public health objectives, so the result has been that India's generic manufacturers have had some space to continue producing affordable and effective medicines.

October 03, 2010

Despite the continuing tense situation, MSF counselors have restarted visiting patients in the hospitals in the capital, Srinagar, and are offering on-the-spot psychological assistance to victims of violence and their families.

September 21, 2010

Violence and curfews have forced MSF to suspend its mental health care programs in the Kashmir Valley.

August 17, 2010

Following a sharp increase in malaria cases in Mumbai, MSF has launched a malaria intervention to help local health authorities fight the disease.

April 19, 2010

Closed-door negotiations between India and the EU are entering a crucial phase; at stake is access to affordable medicines for millions.

Pages